HUMIRA

Humira (adalimumab injection) is a tumor necrosis factor (TNF) blocker used for treatment of: 

Rheumatoid Arthritis (RA): Reducing signs and symptoms, inducing major clinical response, blocking the progression of structural damage, and improving physical function in adults with moderately to severely active disease. 

Psoriatic Arthritis: Reducing signs/symptoms of active arthritis, inhibiting the progression of structural damage, and improving the physical function. 

Ankylosing Spondylitis: Reducing signs and symptoms in patients with active disease. 

Crohn’s Disease: Reducing signs/symptoms and inducing and maintaining the clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. Reducing signs/symptoms and inducing clinical remission in these patients if they have also lost response to or are not tolerant to infliximab. 

Plaque Psoriasis: The treatment of adult patients with moderate to severe chronic plaque psoriasis who are recipients for systemic therapy or phototherapy. 

• Treatment with adalimumab 40 mg should not be initiated in patients with active infections including chronic or localized infections.
• Patients who develop a new infection while undergoing treatment with the inj adalimumab 40 mg should be monitored closely. Discontinue therapy if a patient develops a serious infection.
• Prior to the initiation of therapy with humira 40 mg injection, patients should be assessed for tuberculosis risk factors and should be tested for latent tuberculosis infection.
• Prescribers must exercise the precise caution in considering humira uses in patients with preexisting/recent-onset central nervous system demyelinating disorders.
• Concurrent use of anakinra and other TNF-blockers was associated with a greater proportion of serious infections and neutropenia. Therefore, the combination of humira 40 mg and anakinra is not recommended. 
• Humira therapy may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome. If symptoms develop, treatment with humira injection dosage should be discontinued. 

What documents are required to import HUMIRA to India?

HUMIRA Injection (Adalimumab) can be imported by patients or government hospitals in the name of the patients only.

The following documentation is required to import the product:

1. Valid prescription from a qualified doctor.
2. Patient’s diagnostic reports
3. Patient’s ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

1. Valid prescription from the Doctor
2. Import permit if applicable

Is HUMIRA available in India?

HUMIRA is a prescription drug that legally requires a medical prescription to be dispensed.

Urgent Meds helps import cancer medicines on the named patient supply (NPS). Urgent Meds provides input on:

• Availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• Medicine Price.
• Finding genuine and reliable sources from Canada, Europe, USA, and Australia
• Ensuring 100% transparency.

HUMIRA can be made available in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, and other cities in India.

Urgent Meds can facilitate the supply of HUMIRA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +1-647-818-4196 or email info@urgentmeds.in for HUMIRA injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Urgent Meds is proficient in sourcing Humira Injection (Cancer Treatment Medicines) from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide.

Urgent Meds is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address from New Delhi, India. Your health and well-being are our top priorities.

What is the Generic Name for the trade name drug Humira®?

Adalimumab is the Generic Name for the trade name drug Humira®.

What is the Manufacturer Name of Humira®?

Humira® is manufactured by Abbott Labs Inc. (ABBVIE).

Is Humira® approved by the FDA?

Yes, Humira® is approved by the FDA. The product was approved in December 2002.

What is the dosage and form of Humira® available?

Humira is available as a 1 mL prefilled glass syringe that provides a 40 mg (0.8 mL) injection.

How is Humira (Adalimumab) vial supplied?

Each vial of Humira (Adalimumab) contains 40 mg (0.8 mL). The product is available as either a single-use, prefilled Humira pen (HUMIRA Injection).

What are the storage conditions of Humira (Adalimumab)?

Humira (Adalimumab) must be refrigerated at 36°F to 46°F (2°C to 8°C). Do not freeze.

For more information, please contact +1-647-818-4196 or email info@urgentmeds.in.